Kornimate/medical-research-clean huggingface dataset:
the effect of laparoscopic splenectomy on the immune function for cirrhosis patients

Conditions: Cirrhosis, Liver; Splenectomy; Status

Summary: in this study, the investigators compared the improvement of and azygoportal disconnection related indicators in patients with liver cirrhosis after laparoscopic splenectomy. to determine whether surgical treatment can help enhance postoperative immune function and improve patient prognosis.

the patients were enrolled according to the research criteria, and collected the general basic information of the patients. after the preoperative preparation was perfected, the same surgical team performed laparoscopic splenectomy, and the same nursing team performed the nursing after the operation. then, patients received a unified treatment plan after surgery, including medication, other treatments and follow-up. during the treatment, the immune function related indicators of the patients were monitored before surgery, 3, 6, 12 and 24 months after surgery, including the counts of leukocytes, neutrophils, lymphocytes, and monocytes, and the levels of cd4+, cd8+, cd4+/cd8+, and cd19, cd20.

Eligibility criteria:
inclusion criteria: * a clinical, radiological or histologic diagnosis of cirrhosis of any etiology * splenomegaly with secondary hypersplenism, platelet count \< 50\*10\^9/l * informed consent to participate in the study exclusion criteria: * hepatocellular carcinoma or any other malignancy, * child-pugh grade c * recent peptic ulcer disease * history of hemorrhagic stroke * pregnancy. * uncontrolled hypertension * bleeding portal hypertension * human immunodeficiency virus (hiv) infection

Keywords: cirrhosis splenectomy laparoscopy immune function
does enhancing maternal peer interactions decrease rates of postpartum depression?

Conditions: Postpartum Depression

Summary: the long-term goal of this study is to validate a simple and inexpensive intervention to reduce the incidence and impact of postpartum depression (ppd). the central hypothesis is that enhancing social support of new mothers specifically via an organized peer get-together will decrease rates of postpartum depression. the rationale for the proposed research is that even though ppd is common and risk factors for developing ppd are known, simple and inexpensive interventions to prevent ppd need to be studied. postpartum mothers will be recruited for the study and randomized into control versus intervention group. the intervention group will be placed in a peer discussion group. incidence of ppd will be tracked.

according to a 2014 cochrane review, postpartum depression (ppd) is present in 13% of new mothers by twelve weeks postpartum. infant feeding, sleep routines, growth, and socioemotional and cognitive development can be adversely affected by maternal ppd. these negative effects can last into childhood. previous studies have shown that strong social support is protective against ppd. the 2014 cochrane review on this topic comments that simple, inexpensive interventions to decrease rates of ppd are needed and that interventions led by lay-people and done in groups may be helpful to decrease rates of ppd. more recent studies focus on interventions for mothers already showing symptoms of postpartum depression, not on preventing these symptoms from developing. the proposed work is important, because it capitalizes on recommendations for future research from the 2014 cochrane review on psychosocial and psychological interventions for preventing postpartum depression. the proposed work is also innovative, because it involves a preventive intervention from lay-people in a group setting, with new moms benefiting from each other. at the completion of this project, it is our expectation that mothers in the intervention group will have sustained decreased rates of ppd.

Eligibility criteria:
inclusion criteria: 1. women who deliver at the hershey medical center 2. postpartum women within first week after delivery 3. women who are 18 years of age or older exclusion criteria: 1. postpartum women who delivered newborn before 35 0/7 gestational age. 2. postpartum women whose newborn required any length of stay in the newborn intensive care unit. 3. postpartum women who do not speak english. 4. postpartum women who are less than 18 years old. 5. postpartum women who are unable to provide consent. 6. postpartum women who were on antidepressant or antianxiety medication or undergoing therapy for depression or anxiety during pregnancy or during postpartum hospitalization.
retrospective analysis of colorectal cancer screening results

Conditions: Colorectal Cancer; Advanced Adenocarcinoma; Hyperplastic Polyp; Colorectal Neoplasms; Digestive System Neoplasm; Neoplasms

Summary: the purpose of this study is to retrospectively analyze colorectal cancer screening data of 40-74 year old population in shipai town, dongguan city. in this study, the data of sdc2 gene methylation test and fecal immunochemistry test (q-fit) were screened from about 11,000 subjects who participated in colorectal cancer screening in shipai town people's livelihood project from may 2021 to may 2022. data from 822 subjects with positive sdc2 gene methylation test and/or positive fecal immunochemistry test (q-fit) results and with colonoscopy and/or pathological results were selected for retrospective analysis. this retrospective study evaluated the screening performance of sdc2 gene methylation test and/or fecal immunochemistry test (q-fit) for colorectal cancer using colonoscopy and/or pathological results as the clinical standard method.

this study is a retrospective and observational study. subjects were not be given or offered any treatment during the study. the investigator reviewed the patient's medical history and examination report to determine eligibility based on inclusion and exclusion criteria. this study retrospectively analyse the basic information and the test results of sdc2 gene methylation test and fecal immunochemistry test (q-fit) of about 11,000 subjects who participated in the colorectal cancer screening in shipai town people's livelihood project from may 2021 to may 2022. a total of 822 subjects with positive sdc2 gene methylation test results and / or positive fecal immunochemistry test (q-fit) results were screened out and their colonoscopy results were collected. 822 subjects were classified according to colonoscopy and/or pathological detection results, and the screening performance of the sdc2 gene methylation test and fecal immunochemistry test (q-fit) for colorectal cancer was statistically analyzed.

Eligibility criteria:
inclusion criteria: subjects must meet both of the following criteria to be eligible for the study: 1. subjects with positive sdc2 gene methylation test and/or q-fit; 2. subjects with colonoscopy and/or pathological results. exclusion criteria: subject with any of the following conditions shall be excluded: 1. data missing or damaged; 2. unqualified colonoscopy or unqualified stool test.

Keywords: colorectal cancer colon cancer stool dna test fecal dna test fecal immunochemical test fit methylation biomarkers colonoscopy cancer screening
study of atopic dermatitis in pediatrics

Conditions: Dermatitis, Atopic

Summary: to verify of cetirizine dry syrup to ketotifen dry syrup in the change in the severity of pruritus of the treatment period.


Eligibility criteria:
inclusion criteria: * children diagnosed as atopic dermatitis * giving informed consent * children who have 2 grades or more pruritus score. * children who require the treatment with external steroid preparation other than face and head. * children with a pruritus severity of 2. * mild or severe on the fist day of the treatment period. exclusion criteria: * have spastic disease such as epilepsy * have a history of drug hypersensitivity * are lactating or possibly pregnant female children * have a skin infection, or with zooparasite such as scabies and pediculosis * cannot avoid the use of external steroid classified into strong, strongest or very strong * have eczematous otitis externa with perforation in the eardrum * have dermal ulcer, or profound heat burn or frostbite of the severity higher than the grade 2 * have asthma that requires the treatment with corticosteroid * have pruritus only on face and head * have inappropriate complication of dermal disorder that may influence on the evaluation of the study drug * are undergoing specific desensitization therapy or immunomodulation therapy or phototherapy.

Keywords: atopic pediatric dermatitis
cdc hiv testing guidelines: unresolved ethical concerns

Conditions: HIV Infections

Summary: advocacy groups have voiced concerns about the ethics of some of tenets of the cdc's new hiv testing recommendations for the healthcare setting. three concerns are paramount: (1) the opt-out approach to hiv testing can potentially be coercive and not truly voluntary; (2) by replacing informed consent with general consent for medical care, test participants might not know or be adequately informed of the benefits and consequences of testing; and (3) eliminating hiv prevention counseling from the hiv testing process presumes that test participants are aware of how to prevent an hiv infection, which might not be correct. this study involves conducting interviews of hiv advocates who are raising these concerns, surveying outpatient and emergency department clinical providers about their beliefs and opinions regarding the tenets of the new guidelines, and then conducting a multi-center, randomized, controlled trial in which the ethical concerns of opt-out vs. opt-in testing are directly compared. we will conduct a multi-center, randomized, controlled, trial whereby patients will be surveyed on their perspectives and perceptions regarding opt-out or opt-in rapid hiv testing. we will survey the participants regarding their perception of coercion, their understanding of the elements contained in the informed consent process, their hiv risk factors, and their knowledge of hiv prevention. we will evaluate whether or not the cdc-recommended approaches regarding opt-out testing, consent, and decoupling of prevention counseling are supported. if there are no differences regarding these ethical concerns between testing approaches, then the opt-out approach would be considered not to be inferior to the opt-in approach.


Eligibility criteria:
inclusion criteria: * 18-64-year-old patients in the outpatient family practice and medical clinics and emergency departments of memorial hospital, miriam hospital, and rhode island hospital who speak english or spanish and are not hiv infected exclusion criteria: * hiv infection * inability to speak english or spanish * a physical, psychiatric, or mental disability that prevents participation in the study * involvement in an hiv vaccine study * prisoner

Keywords: hiv testing hiv seronegativity
smoking cessation study for patients with schizophrenia or schizoaffective disorder

Conditions: Smoking Cessation

Summary: study will determine whether patients with schizophrenia or schizoaffective disorder can be helped to quit smoking safely while using varenicline and receiving smoking cessation counseling.

this is a safety study.

Eligibility criteria:
inclusion criteria: * have a diagnosis (using the scid-i/p at screening visit) of schizophrenia or schizoaffective disorder and judged to be stable (without hospitalization or acute exacerbation and functioning in society) on psychiatric treatment for at least the past 6 month. * current cigarette smokers (at least 15/day during the past year with no period of abstinence greater than 3 months in the past year) male or female, between the ages of 18 and 75 inclusive, who are motivated to stop smoking. * score 7 or higher on the contemplation ladder at the screening, week -1, and baseline visits. exclusion criteria: * panss score \>70 at screen or baseline visit. * subjects hospitalized within the past six months due to suicidal ideation or suicidal behavior or subjects considered to have serious suicidal ideation or suicidal behavior within the past six moth. * subjects having active suicidal ideation or behavior identified at screen, week -1, or baseline visit. * subjects taking bupropion.
minimizing pain experience in trigger finger steroid injection.

Conditions: Trigger Finger

Summary: to study the pain experience of trigger finger steroid injection with 26 gauge needle as compared to 23 gauge needle.

compare pain experience of trigger finger steroid injection between 26 gauge needle and 23 gauge needle.

Eligibility criteria:
inclusion criteria: * age above 18 year old * male or female(non-pregnant) * single trigger finger * clinically diagnosed trigger finger- green classification grade i or ii * no prior surgery to the involved finger * subject is able to provide voluntary, written informed consent exclusion criteria: * age less than 18 year old * allergy to lignocaine or corticosteroid * trigger finger with green classification grade iii or iv * previous surgery on the affected finger * any wound, neurovascular injury, or skin disease at injection site * concomitant ipsilateral fingers/wrist/forearm/arm injury * preexisting congenital/acquired deformities of hand (such as rheumatoid arthritis, contracture) * insensate hand

Keywords: steroid injection pain needle gauge trigger finger
observational study of prophylaxis and treatment of acute perioperative bleeding with beriplex® p/n (probe study)

Conditions: Coagulation Protein Disorders; Blood Loss, Surgical; Perioperative Care

Summary: beriplex® p/n is made from human plasma (the liquid part of the blood) and contains the coagulation factors ii, vii, ix and x which are important for blood clotting (coagulation). lack of any of these factors means that blood does not clot as quickly as it should and so there is an increased tendency to bleed. this observational study was designed to evaluate the effectiveness of beriplex® p/n in the prevention (prophylaxis) and treatment of bleeding during surgery (perioperative bleeding) in a routine clinical setting.


Eligibility criteria:
inclusion criteria (all): for all cohorts: •≥ 16 years of age * received treatment with: * beriplex® p/n * or ffp and beriplex® p/n (in subsequent order) * or ffp only * inr and/or pt results available in connection with administration of beriplex® p/n or ffp: * within 3 hours directly before and after administration of beriplex® p/n or ffp in case of beriplex® p/n use subsequent to ffp, additional results of inr and pt between the administration of the two products cohort p (prophylaxis group): * chronic liver disease, acute liver failure, or other conditions requiring correction of coagulopathy * coagulopathy (inr \> 1.4 and/or pt ≥ 3 sec of upper limit of normal \[uln\]) * any planned major or minimally invasive procedure, except liver transplantation cohort t (treatment group): * acute perioperative bleeding (as assessed by the investigator) exclusion criteria: * treatment with prothrombin complex concentrates (pccs) other than beriplex® p/n * acquired deficiency of the vitamin k-dependent coagulation factors (e.g., as induced by treatment with oral vitamin k antagonists)

Keywords: coagulopathy perioperative bleeding prothrombin complex liver disease
pira vs standard preoperative education

Conditions: Anesthesia; Anesthesia Emergence Delirium; Procedural Anxiety

Summary: the purpose of this study is to determine the feasibility and acceptability of enhanced preoperative education using a pediatric interactive relational agent (pira), designed for children ages 4 through10 years and their families, compared to the standard preoperative education currently provided. the study will also look at any differences in anxiety between the two educational groups.


Eligibility criteria:
inclusion criteria: * parents (age 18+) and their children, ages 4 through 10 years old, who are undergoing general anesthesia and elective, outpatient orl surgery at bch waltham * american society of anesthesiology (asa) physical status i or ii * both parents and their children must be fluent in english exclusion criteria: * parents without reliable internet access through a tablet or computer * parents of children with diagnosed developmental delays * parents who have children who have had previous surgical history under general anesthesia * parents of children involved in other anesthesia-related studies at bch

Keywords: education
safety and efficacy of eszopiclone with mild to moderate obstructive sleep apnea syndrome (osas)

Conditions: Obstructive Sleep Apnea Syndrome

Summary: the purpose of this study is to evaluate the hypnotic efficacy of ezopiclone in subjects with mild to moderate osas.

sleep apnea is a sleep disorder characterized by pauses in breathing during sleep. this study will compare the use of eszopiclone to placebo for subjects with mild to moderate obstructive sleep apnea syndrome (osas). frequency and duration of apnea and hypopnea episodes, oxygen saturation, objective sleep parameters and safety information will be collected in this study. this study was previously posted by sepracor inc. in october 2009, sepracor inc. was acquired by dainippon sumitomo pharma., and in october 2010, sepracor inc's name was changed to sunovion pharmaceuticals inc.

Eligibility criteria:
inclusion criteria: * the subject is capable of understanding and complying with the protocol and has signed the informed consent document, including the privacy authorization. female subjects of childbearing potential must sign the women of childbearing potential addendum to the informed consent form. * male and female subjects between 35 and 64 years of age, inclusive, with mild to moderate obstructive sleep apnea syndrome (ahi range ≥10 and ≤40). * females considered not of childbearing potential must be surgically sterile or greater than one-year post menopausal, defined as a complete cessation of menstruation for at least one year. * subjects must use continuous positive airway pressure (cpap). * subjects must be in general good health based on screening physical examination (defined as the absence of any clinically relevant abnormalities), medical history, 12-lead ecg, and clinical laboratory values (hematology, serum chemistry and urinalysis). exclusion criteria: * subject has any clinically significant unstable medical abnormality, chronic disease, or a history of a clinically significant abnormality of the cardiovascular, respiratory, hepatic, or renal systems. * subject has a history of, or current malignancy except for non melanomatous skin cancer. * subject tests positive at screening for hepatitis b surface antigen or hepatitis c antibody, or the subject has a history of a positive result. * subject is known to be seropositive for human immunodeficiency virus (hiv).

Keywords: obstructive sleep apnea syndrome osas
safety and efficacy study of remote ischemic conditioning combined with endovascular thrombectomy for acute ischemic stroke due to large vessel occlusion of anterior circulation

Conditions: Acute Ischemic Stroke

Summary: the purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for patients of acute ischemic stroke who underwent endovascular thrombectomy due to large vessel occlusion of anterior circulation.

in this study, 498 cases of ischemic stroke who undergo endovascular thrombectomy within 24 hours from the onset are included in 10 centers in china according to the principle of random, and parallel control. the experimental group receive basic treatment and remote ischemic conditioning for 200mmhg, 2 times per day for 7 consecutive days. the control group receive basic treatment and remote ischemic conditioning control for 60mmhg, 2 times per day for 7 consecutive days. two groups will be followed up for 90 days to evaluate the efficacy and safety of remote ischemic conditioning for patients of acute ischemic stroke who underwent endovascular thrombectomy due to large vessel occlusion of anterior circulation.

Eligibility criteria:
inclusion criteria: * 1) age ≥ 18 years, male or female * 2) diagnosis of acute ischemic stroke within 24 hours of symptom onset and underwent endovascular thrombectomy (evt) adhering to current guidelines for large vessel occlusion in the anterior circulation (confirmed by computed tomography angiography or digital subtraction angiography) * 3) pre-evt nihss ≥ 6 * 4) premorbid mrs ≤ 2 * 5) written informed consent obtained from the patient or legally responsible person exclusion criteria: * 1) contraindication of endovascular thrombectomy * 2) contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture, or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, and subclavian steal syndrome * 3) head ct showing cerebral hernia and midline displacement * 4) pregnancy or lactation * 5) previous remote ischemic conditioning therapy or similar treatment * 6) severe hepatic and renal dysfunction * 7) life expectancy of less than 3 months or inability to complete the study for other reasons * 8) unwilling to be followed up or poor compliance * 9) current or past participation in other clinical research, or participation in this study within 3 months prior to admission * 10) other conditions that the researchers think make the patient unsuitable for the study
clinical effect of miboflo in dry eye patients

Conditions: Dry Eye Syndromes; Meibomian Gland Dysfunction

Summary: the aim of this prospective study is to compare the changes between the patients receiving traditional treatment and the patients with miboflo, evaluating the effectiveness of miboflo.

the miboflo thermoflo uses a proprietary thermoelectric heat pump to help meibum maximize liquefaction, improving the preservation and function of the tear film's evaporative component. it supplies continuous controlled heat to the outer skin of the eyelids, absorbing deep into the tissue and breaks down the hardened oils in the meibomian glands. we are trying to find a effective, safe and economical therapy for dry eye patients.

Eligibility criteria:
inclusion criteria: * 18 years of age of older; * meet the diagnostic criteria for dry eye developed by dews ii: osdi score≥15 points, tbut≤10 minutes; * meet the signs of meibomian gland dysfunction exclusion criteria: * had skin allergies or inflammation; * had active ocular infection or inflammation; * had history of ocular surgery, eyelid surgery or neurological paralysis within 6 months; * had history of systemic disease affecting ocular surface function, such as stevens-johnson syndrome, sjögren syndrome etc.

Keywords: dry eye meibomian gland dysfunction therapy